表3. 影响慢性髓性白血病慢性期患者治疗反应的多因素分析结果.
因素 | CCyR |
MMR |
MR4.5 |
||||||
OR | 95% CI | P值 | OR | 95% CI | P值 | OR | 95% CI | P值 | |
男性 | 0.7 | 0.6~0.9 | 0.001 | 0.6 | 0.4~0.9 | 0.003 | |||
年龄 | 0.023 | ||||||||
18~<40岁(参考组) | |||||||||
40~<60岁 | 1.4 | 1.0~1.8 | 0.030 | ||||||
≥60岁 | 0.7 | 0.4~1.3 | 0.305 | ||||||
Sokal积分 | <0.001 | 0.005 | |||||||
低危(参考组) | |||||||||
中危 | 0.7 | 0.6~0.9 | 0.008 | 0.7 | 0.6~0.9 | 0.005 | |||
高危 | 0.6 | 0.5~0.8 | <0.001 | 0.7 | 0.5~0.9 | 0.013 | |||
诊断时WBC≥100×109/L | 0.7 | 0.6~0.9 | 0.002 | 0.6 | 0.4~0.7 | <0.001 | 0.4 | 0.3~0.5 | <0.001 |
诊断时HGB<120g/L | 0.7 | 0.6~1.0 | 0.090 | ||||||
服用伊马替尼(尼洛替尼为参考组) | 0.6 | 0.5~0.8 | 0.001 | 0.6 | 0.5~0.8 | 0.001 | 0.6 | 0.5~0.9 | 0.032 |
注:CCyR:完全细胞遗传学反应;MMR:主要分子学反应;MR4.5:分子学反应4.5